Exagen Inc. (NASDAQ:XGN - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Exagen in a research report issued on Wednesday, March 12th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($0.59) per share for the year, down from their previous estimate of ($0.41). Cantor Fitzgerald has a "Overweight" rating and a $8.00 price objective on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share.
A number of other research firms also recently weighed in on XGN. William Blair reissued an "outperform" rating on shares of Exagen in a research note on Wednesday, March 12th. Canaccord Genuity Group increased their price target on Exagen from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Friday, January 3rd.
Get Our Latest Analysis on XGN
Exagen Price Performance
NASDAQ:XGN remained flat at $3.62 during trading hours on Friday. The company's stock had a trading volume of 40,498 shares, compared to its average volume of 81,552. The company's fifty day moving average is $3.78 and its 200 day moving average is $3.58. Exagen has a 12-month low of $1.30 and a 12-month high of $6.22. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. The firm has a market capitalization of $64.79 million, a P/E ratio of -3.85 and a beta of 1.40.
Institutional Trading of Exagen
Several hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp raised its stake in Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after buying an additional 2,630 shares during the period. Palumbo Wealth Management LLC raised its stake in Exagen by 13.5% during the 4th quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company's stock worth $355,000 after buying an additional 10,340 shares during the period. Geode Capital Management LLC raised its stake in Exagen by 11.9% during the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock worth $402,000 after buying an additional 10,442 shares during the period. Corient Private Wealth LLC acquired a new stake in Exagen during the 4th quarter worth $45,000. Finally, Virtu Financial LLC acquired a new stake in Exagen during the 4th quarter worth $46,000. Institutional investors and hedge funds own 75.25% of the company's stock.
About Exagen
(
Get Free Report)
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Featured Articles
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
